NASDAQ · Drug Manufacturers - Specialty & Generic

SBFM (SBFM) Stock

$1.17 +0.00% NASDAQ: SBFM Healthcare

Valuation

MetricValue
Price$1.17
Market Cap$585691
P/E Ratio-0.15
P/B Ratio0.05
P/S Ratio0.03
EPS (TTM)$-14.40
52-Week High$24.30
52-Week Low$1.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-27.32%
ROA-10.02%
ROCE-17.39%
Gross Margin32.49%
Operating Margin-12.90%
Net Margin-17.01%
Debt/Equity0.03
Current Ratio4.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$4.0M$24.0M$35.0M$36.0M
Operating Profit$-2.0M$-9.0M$-5.0M$-6.0M$-4.0M
Net Profit$-12.0M$-27.0M$-5.0M$-5.0M$-6.0M
EPS$-95200.00$-35236.40$-3513.60$-73.20$-14.40
Op Margin-1068.2%-199.6%-19.9%-16.7%-12.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0M$30.0M$27.0M$31.0M$30.0M
Total Liabilities$2.0M$8.0M$6.0M$7.0M$7.0M
Cash$2.0M$22.0M$16.0M$10.0M$9.0M
Borrowings$2.0M$1.0M$1.0M$1.0M$1.0M

Latest News

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings ACCESS Newswire · Jul 20, 2026 Sunshine Biopharma Secures Approval for Generic Anastrozole in Canada MT Newswires · Jun 25, 2026 Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R) ACCESS Newswire · Jun 25, 2026 Sunshine Biopharma Says Rivaroxaban Received Canadian Approval MT Newswires · Jun 1, 2026 Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R) ACCESS Newswire · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-5.0M$-9.0M$-13.0M$-5.0M
Investing Cash Flow$0$-15.0M$-1.0M$-5.0M$-1.0M
Financing Cash Flow$0$-2.0M$-1.0M$-3.0M$0
Net Cash Flow$1.0M$20.0M$-6.0M$-7.0M$-1.0M
Free Cash Flow$-2.0M$-6.0M$-10.0M$-15.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA1.19
FCF Yield-500.20%
Quick Ratio1.98
Interest Coverage—
Return 1Y-87.67%
Return 3Y-99.98%
Return 5Y—

Ownership

Insiders Held0.43%
Institutions Held11.44%
Institutions Float Held11.49%
Institutional HolderSharesReport Date
Citadel Advisors Llc4,6252026-03-31
Two Sigma Securities, LLC2,3482026-03-31
Xtx Topco Ltd2,1462026-03-31
Morgan Stanley1,4632026-03-31
Commonwealth Equity Services, LLC1,3442026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
BFRI $1.17 -4.88% -0.90 $14.98M 0.00%
CHEKCheck-Cap Ltd. $1.86 +1.64% -0.43 $10.88M 0.00%
EVOKEvoke Pharma, Inc. $11.00 +0.00% -6.96 $18.95M 0.00%
HCWB $2.65 +6.00% -0.23 $921249 0.00%

About SBFM

SBFM is led by CEO Steve N. Slilaty, employs 52 people, headquartered in CA, publicly traded since 2022.

SBFM stock trades at $1.17 with a market capitalization of $585691. The stock is valued at a price-to-earnings (P/E) ratio of -0.15, price-to-book of 0.05, price-to-sales of 0.03. Over the past 52 weeks the stock has ranged between $1.17 and $24.30, and currently trades 95.2% below its 52-week high.

On profitability, SBFM generates a return on equity (ROE) of -27.32%, return on capital employed of -17.39%, an operating margin of -12.90%, a net profit margin of -17.01%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides